Genmab A/S Valuation
| GE9 Stock | EUR 274.90 0.50 0.18% |
At this time, the firm appears to be fairly valued. Genmab A/S retains a regular Real Value of €273.5 per share. The prevalent price of the firm is €274.9. Our model calculates the value of Genmab A/S from evaluating the firm fundamentals such as Return On Asset of 0.13, return on equity of 0.29, and Current Valuation of 13.51 B as well as inspecting its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Genmab A/S's price fluctuation is very steady at this time. Calculation of the real value of Genmab A/S is based on 3 months time horizon. Increasing Genmab A/S's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Genmab stock is determined by what a typical buyer is willing to pay for full or partial control of Genmab AS. Since Genmab A/S is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genmab Stock. However, Genmab A/S's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 274.9 | Real 273.5 | Hype 272.8 | Naive 267.24 |
The real value of Genmab Stock, also known as its intrinsic value, is the underlying worth of Genmab A/S Company, which is reflected in its stock price. It is based on Genmab A/S's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Genmab A/S's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Genmab AS helps investors to forecast how Genmab stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genmab A/S more accurately as focusing exclusively on Genmab A/S's fundamentals will not take into account other important factors: Genmab A/S Cash |
|
Genmab A/S Total Value Analysis
Genmab AS is currently estimated to have takeover price of 13.51 B with market capitalization of 16.84 B, debt of 0, and cash on hands of 921.63 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Genmab A/S fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
13.51 B | 16.84 B | 0 | 921.63 M |
Genmab A/S Investor Information
About 44.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Based on the key indicators related to Genmab A/S's liquidity, profitability, solvency, and operating efficiency, Genmab AS is performing exceptionally good at this time. It has a great probability to report excellent financial results in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 3.2 B | 3 B |
|
|
Genmab A/S Asset Utilization
One of the ways to look at asset utilization of Genmab is to check how much profit was generated for every dollar of assets it reports. Genmab A/S harnesses its resources almost 0.1338 (percent), generating 0.13 cents for each euro of resources held by the firm. An expanding asset utilization attests that the company is being more effective with each euro of resources it retains. Simply put, asset utilization of Genmab A/S shows how effective it operates for each euro spent on its resources.Genmab A/S Profitability Analysis
Based on Genmab A/S's profitability indicators, Genmab A/S's profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess Genmab A/S's ability to earn profits and add value for shareholders.Net Income | First Reported 2010-12-31 | Previous Quarter 2.5 B | Current Value 2.6 B | Quarterly Volatility 953.9 M |
For Genmab A/S profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Genmab A/S to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Genmab A/S utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Genmab A/S's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Genmab A/S over time as well as its relative position and ranking within its peers.
Genmab A/S Earnings per Share Projection vs Actual
By analyzing Genmab A/S's earnings estimates, investors can diagnose different trends across Genmab A/S's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Genmab AS is based on EPS before non-recurring items and includes expenses related to employee stock options.Genmab A/S Ownership Allocation
Genmab AS has a total of 61.49 Million outstanding shares. 30% of Genmab A/S outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Genmab A/S Profitability Analysis
The company reported the revenue of 3.85 B. Net Income was 4.35 B with profit before overhead, payroll, taxes, and interest of 3.63 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Genmab A/S's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Genmab A/S and how it compares across the competition.
About Genmab A/S Valuation
The stock valuation mechanism determines Genmab A/S's current worth on a weekly basis. Our valuation model uses a comparative analysis of Genmab A/S. We calculate exposure to Genmab A/S's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genmab A/S's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 6.2 B | 6.5 B | |
| Pretax Profit Margin | 0.49 | 0.47 | |
| Operating Profit Margin | 0.36 | 0.34 | |
| Net Profit Margin | 0.42 | 0.40 | |
| Gross Profit Margin | 0.86 | 0.90 |
Complementary Tools for Genmab Stock analysis
When running Genmab A/S's price analysis, check to measure Genmab A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab A/S is operating at the current time. Most of Genmab A/S's value examination focuses on studying past and present price action to predict the probability of Genmab A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab A/S's price. Additionally, you may evaluate how the addition of Genmab A/S to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |